BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced its upcoming second quarter 2024 financial results and business highlights conference call. The event is scheduled for Thursday, August 8, 2024, at 4:30 p.m. ET.
Investors and interested parties can access the webcast through the provided link or join via phone using the dial-in numbers. The financial results press release will be available on the company's website prior to the call. A replay of the conference call will also be accessible through the Investors section of BioAtla's website.
BioAtla (Nasdaq: BCAB), un'azienda biotecnologica globale in fase clinica specializzata in terapie anticorpali Conditionally Active Biologic (CAB) per tumori solidi, ha annunciato la sua prossima conferenza sui risultati finanziari e sugli aspetti aziendali del secondo trimestre 2024. L'evento è programmato per giovedì 8 agosto 2024, alle 16:30 ET.
Investitori e parti interessate possono accedere al webcast tramite il link fornito o unirsi telefonicamente utilizzando i numeri di accesso. Il comunicato stampa sui risultati finanziari sarà disponibile sul sito web dell'azienda prima della chiamata. Una registrazione della conferenza sarà anche accessibile nella sezione Investitori del sito di BioAtla.
BioAtla (Nasdaq: BCAB), una compañía biotecnológica global en etapa clínica especializada en terapias anticuerpos Conditionally Active Biologic (CAB) para tumores sólidos, ha anunciado su próxima conferencia sobre los resultados financieros y aspectos comerciales del segundo trimestre de 2024. El evento está programado para jueves 8 de agosto de 2024, a las 4:30 p.m. ET.
Los inversionistas y partes interesadas pueden acceder al webcast a través del enlace proporcionado o unirse por teléfono utilizando los números de marcado. El comunicado de prensa de los resultados financieros estará disponible en el sitio web de la empresa antes de la llamada. También se podrá acceder a una repetición de la conferencia en la sección de Inversionistas del sitio web de BioAtla.
BioAtla (Nasdaq: BCAB)는 고형 종양을 위한 조건부 활성 생물학(CAB) 항체 치료제에 특화된 글로벌 임상 단계 생명공학 회사로, 2024년 2분기 재무 결과 및 비즈니스 하이라이트에 관한 컨퍼런스 콜을 발표했습니다. 이 행사는 2024년 8월 8일 목요일 오후 4시 30분 ET에 예정되어 있습니다.
투자자 및 관련자들은 제공된 링크를 통해 웹캐스트에 접근하거나 전화로 접속할 수 있는 다이얼 인 번호를 사용할 수 있습니다. 재무 결과에 대한 보도자료는 전화 회의 전에 회사 웹사이트에서 확인할 수 있습니다. BioAtla의 웹사이트 투자자 섹션에서도 컨퍼런스 콜 재생을 이용할 수 있습니다.
BioAtla (Nasdaq: BCAB), une entreprise biotechnologique mondiale en phase clinique spécialisée dans les thérapies anticorps Conditionally Active Biologic (CAB) pour les tumeurs solides, a annoncé sa prochaine conférence téléphonique sur les résultats financiers et les points saillants commerciaux du deuxième trimestre 2024. L'événement est prévu pour jeudi 8 août 2024, à 16h30 ET.
Les investisseurs et les parties intéressées peuvent accéder au webinaire via le lien fourni ou participer par téléphone en utilisant les numéros de composition. Le communiqué de presse concernant les résultats financiers sera disponible sur le site Web de l'entreprise avant l'appel. Un enregistrement de la conférence téléphonique sera également accessible dans la section investisseurs du site de BioAtla.
BioAtla (Nasdaq: BCAB), ein global tätiges biotechnologisches Unternehmen in klinischen Phasen, das sich auf bedingt aktive biologische (CAB) Antikörpertherapeutika für solide Tumoren spezialisiert hat, hat eine bevorstehende Telefonkonferenz zu den finanziellen Ergebnissen und geschäftlichen Highlights des zweiten Quartals 2024 angekündigt. Die Veranstaltung ist für Donnerstag, den 8. August 2024, um 16:30 Uhr ET geplant.
Investoren und interessierte Parteien können über den bereitgestellten Link auf das Webcast zugreifen oder sich telefonisch über die Einwahlnummern einwählen. Die Pressemitteilung zu den finanziellen Ergebnissen wird vor dem Anruf auf der Unternehmenswebsite verfügbar sein. Auch eine Wiederholung der Telefonkonferenz wird im Bereich Investoren der BioAtla-Website zugänglich sein.
- None.
- None.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 8, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024 and provide business highlights.
Conference Call and Webcast Information
Date: Thursday, August 8, 2024
Time: 4:30 p.m. ET
Webcast Link: BioAtla Second Quarter 2024 Earnings Conference Call
Dial-in Numbers: (800) 579-2543 (domestic), (785) 424-1789 (international)
Conference ID: BIOATLA
The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. BioAtla has an FDA-cleared IND for its next-gen CAB-Nectin4-ADC, BA3361, the Company’s first glycoconjugate. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When will BioAtla (BCAB) release its Q2 2024 financial results?
How can investors access BioAtla's (BCAB) Q2 2024 earnings conference call?
What is BioAtla's (BCAB) main focus in biotechnology?
Where can investors find BioAtla's (BCAB) Q2 2024 financial results press release?
